Celebrate wins like better blood pressure, more energy, or fewer cravings as you move from active weight loss to maintenance
Early losses often reflect reduced water retention and decreased food intake rather than fat loss alone
Pablo de la Cueva has participated as consultant and/or investigator and/or speaker for the following pharmaceutical companies: Abbvie, Almirall, BMS, Boehringer-Ingelheim, Celgene, Janssen Cilag, LEO Pharma, Lilly, MSD, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, and UCB
The final search was performed on January 14, 2024, using the following medical subject heading terms: Semaglutide, Ozempic, Wegovy, Rybelsus, taspoglutide, liraglutide, Victoza, Saxenda, dulaglutide, Trulicity, albiglutide, Eperzan, exenatide, exendin, Byetta, lixisenatide, Lyxumia, tirzepatide, glucagon-like peptide-1 receptor agonists, GLP-1, incretin, endoscopy, esophagogastroduodenoscopy, anesthesia, and perioperative